Hjem › Akut myelogen leukemi › Colorado
Kliniske studier for Akut myelogen leukemi i Colorado
22 studier for Akut myelogen leukemi søker deltakere på steder i Colorado.
Byer i Colorado
Offisiell studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- og 15 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Rocky Mountain Cancer Centers, Aurora
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06852222A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital Colorado, Aurora
RekruttererFase 1
Opp til 21 år · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07012044A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
RekruttererFase 3
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Colorado, Aurora
RekruttererFase 1/2
30 Days · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04065399Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
RekruttererFase 3
Alder 1 til 25 · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07022678CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
- University of Colorado Hospital, Aurora
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07347418CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 til 85 · Alle kjønn · Oppdatert 26. aug. 2026 · NCT06834282Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Anshutz Cancer Pavilion, Aurora
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT06533761The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Children's Hospital Colorado, Aurora
RekruttererFase 3
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Hospital Colorado, Aurora
RekruttererFase 1
Alder 1 til 30 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06177067A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Hospital Colorado, Aurora
- University of Colorado Hospital, Aurora
- Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- University of Colorado, Aurora
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05401097A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 24. mar. 2026 · NCT04988555A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Rocky Mountain Cancer Centers, Aurora
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 31. okt. 2025 · NCT06549790Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- University of Colorado Denver I Anschutz Medical Campus, Denver
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 120 · Alle kjønn · Oppdatert 25. jul. 2025 · NCT05237258APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 11. mai 2025 · NCT06634394Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.